Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 2/20 | 0.64 |
| ▸ | PPARG | P37231 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | KDR | P35968 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | F10 | P00742 | 3/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL418419 | 0.91 | SERPINE1 (0.77) | SERPINE1PPARGL3MBTL1KDRGAA | |
| SCHEMBL420125 | 0.89 | SERPINE1 (0.67) | SERPINE1PPARGL3MBTL1KDRGAA | |
| SCHEMBL417231 | 0.88 | SERPINE1 (0.66) | SERPINE1PPARGL3MBTL1KDRGAA | |
| SCHEMBL7036040 | 0.87 | KMT2A (0.60) | SERPINE1PPARGL3MBTL1KMT2AMEN1 | |
| SCHEMBL417230 | 0.87 | SERPINE1 (0.83) | SERPINE1PPARGL3MBTL1KDRGAA | |
| SCHEMBL7034499 | 0.82 | SERPINE1 (0.52) | SERPINE1PPARGKDRKMT2AMEN1 | |
| SCHEMBL417156 | 0.80 | SERPINE1 (0.61) | SERPINE1L3MBTL1GAAKMT2AMEN1 | |
| SCHEMBL1015922 | 0.80 | PPARG (0.51) | SERPINE1PPARGKDRGAAMAPT | |
| SCHEMBL422042 | 0.80 | SERPINE1 (0.81) | SERPINE1PPARGL3MBTL1KDRGAA | |
| SCHEMBL29838623 | 0.80 | SERPINE1 (0.81) | SERPINE1PPARGL3MBTL1KDRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2607348-B1 | Plasminogen Activator Inhibitor-1 Inhibitor | RENASCIENCE INC (JP) | 2021-03-17 | — | — | EP | disclosed |
| US-20140296256-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | RENASCIENCE CO LTD (JP) | 2014-10-02 | — | — | US | disclosed |
| US-8785473-B2 | Plasminogen activator inhibitor-1 inhibitor | RENASCIENCE CO., LTD. (JP) | 2014-07-22 | — | — | US | disclosed |
| EP-2607348-A2 | Plasminogen Activator Inhibitor-1 Inhibitor | Renascience CO., LTD. (JP) | 2013-06-26 | — | — | EP | disclosed |
| EP-2415755-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | Renascience CO., LTD. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120022080-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | RENASCIENCE CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296256-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | SERPINE1, SERPINC1, SERPINB1 | SERPINE1 1/4885PPARG 2361/4885L3MBTL1 2538/4885 |
| US-20120022080-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | SERPINE1, SERPINC1, SERPINB1 | SERPINE1 1/4885PPARG 2361/4885L3MBTL1 2538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.